Deng Y, Nong Z, Wei M, Xu Y, Luo Y, Li X
Ren Fail. 2024; 46(2):2393754.
PMID: 39177227
PMC: 11346320.
DOI: 10.1080/0886022X.2024.2393754.
Liabeuf S, Hafez G, Pesic V, Spasovski G, Bobot M, Maciulaitis R
Clin Kidney J. 2024; 17(8):sfae174.
PMID: 39114495
PMC: 11304602.
DOI: 10.1093/ckj/sfae174.
Dong X, Zhang J, Li W, Li Y, Jia L, Liu Z
Pharm Biol. 2024; 62(1):356-366.
PMID: 38720666
PMC: 11085992.
DOI: 10.1080/13880209.2024.2345080.
Feng Z, Zhang Y, Lai Y, Jia C, Wu F, Chen D
Front Immunol. 2024; 14:1277554.
PMID: 38283353
PMC: 10811222.
DOI: 10.3389/fimmu.2023.1277554.
Andrade-Oliveira V, Foresto-Neto O, Camara N
Front Pharmacol. 2024; 14:1362010.
PMID: 38269280
PMC: 10807036.
DOI: 10.3389/fphar.2023.1362010.
Enteroendocrine cells and gut hormones as potential targets in the crossroad of the gut-kidney axis communication.
Nery Neto J, Yariwake V, Camara N, Andrade-Oliveira V
Front Pharmacol. 2023; 14:1248757.
PMID: 37927592
PMC: 10620747.
DOI: 10.3389/fphar.2023.1248757.
Alterations of gut microbiota and metabolome in early chronic kidney disease patients complicated with hyperuricemia.
Liu P, Yang J, Chen Y, Zhu Y, Tang Y, Xu X
Heliyon. 2023; 9(9):e20328.
PMID: 37809388
PMC: 10560056.
DOI: 10.1016/j.heliyon.2023.e20328.
Targeting intestinal microecology: potential intervention strategies of traditional Chinese medicine for managing hypertension.
Yang Z, Lin S, Liu Y, Song Z, Ge Z, Fan Y
Front Pharmacol. 2023; 14:1171119.
PMID: 37324472
PMC: 10264781.
DOI: 10.3389/fphar.2023.1171119.
Causal effects of gut microbiota on the risk of chronic kidney disease: a Mendelian randomization study.
Luo M, Cai J, Luo S, Hong X, Xu L, Lin H
Front Cell Infect Microbiol. 2023; 13:1142140.
PMID: 37065213
PMC: 10102584.
DOI: 10.3389/fcimb.2023.1142140.
Causal Effects of Specific Gut Microbiota on Chronic Kidney Diseases and Renal Function-A Two-Sample Mendelian Randomization Study.
Li N, Wang Y, Wei P, Min Y, Yu M, Zhou G
Nutrients. 2023; 15(2).
PMID: 36678231
PMC: 9863044.
DOI: 10.3390/nu15020360.
The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation.
Rahman M, Islam F, -Or-Rashid M, Al Mamun A, Rahaman M, Islam M
Front Cell Infect Microbiol. 2022; 12:903570.
PMID: 35795187
PMC: 9251340.
DOI: 10.3389/fcimb.2022.903570.
Probiotics-Supplemented Low-Protein Diet for Microbiota Modulation in Patients with Advanced Chronic Kidney Disease (ProLowCKD): Results from a Placebo-Controlled Randomized Trial.
Andreana De Mauri , Carrera D, Bagnati M, Rolla R, Vidali M, Chiarinotti D
Nutrients. 2022; 14(8).
PMID: 35458199
PMC: 9025298.
DOI: 10.3390/nu14081637.
Biomarkers of non-communicable chronic disease: an update on contemporary methods.
Al-Hadlaq S, Balto H, Hassan W, Marraiki N, El-Ansary A
PeerJ. 2022; 10:e12977.
PMID: 35233297
PMC: 8882335.
DOI: 10.7717/peerj.12977.
The change of gut microbiota-derived short-chain fatty acids in diabetic kidney disease.
Zhong C, Dai Z, Chai L, Wu L, Li J, Guo W
J Clin Lab Anal. 2021; 35(12):e24062.
PMID: 34689373
PMC: 8649351.
DOI: 10.1002/jcla.24062.
Effects of prebiotic oligofructose-enriched inulin on gut-derived uremic toxins and disease progression in rats with adenine-induced chronic kidney disease.
Melekoglu E, Cetinkaya M, Kepekci-Tekkeli S, Kul O, Samur G
PLoS One. 2021; 16(10):e0258145.
PMID: 34614017
PMC: 8494360.
DOI: 10.1371/journal.pone.0258145.
End-Stage Renal Disease-Related Accelerated Immune Senescence: Is Rejuvenation of the Immune System a Therapeutic Goal?.
Ducloux D, Legendre M, Bamoulid J, Saas P, Courivaud C, Crepin T
Front Med (Lausanne). 2021; 8:720402.
PMID: 34540869
PMC: 8446427.
DOI: 10.3389/fmed.2021.720402.
The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease.
Zaky A, Glastras S, Wong M, Pollock C, Saad S
Int J Mol Sci. 2021; 22(17).
PMID: 34502562
PMC: 8431784.
DOI: 10.3390/ijms22179641.
Gut Microbiota Composition and Its Metabolites in Different Stages of Chronic Kidney Disease.
Chen T, Liu C, Ho Y, Huang C, Hung C, Smith B
J Clin Med. 2021; 10(17).
PMID: 34501329
PMC: 8432073.
DOI: 10.3390/jcm10173881.
The Immunomodulatory Effect of the Gut Microbiota in Kidney Disease.
Chi M, Ma K, Wang J, Ding Z, Li Y, Zhu S
J Immunol Res. 2021; 2021:5516035.
PMID: 34095319
PMC: 8140847.
DOI: 10.1155/2021/5516035.
Gut Microbiome Composition Remains Stable in Individuals with Diabetes-Related Early to Late Stage Chronic Kidney Disease.
Lecamwasam A, Nelson T, Rivera L, Ekinci E, Saffery R, Dwyer K
Biomedicines. 2021; 9(1).
PMID: 33383810
PMC: 7824346.
DOI: 10.3390/biomedicines9010019.